Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells
Currently, a common therapeutic approach in cancer treatment encompasses a drug combination to attain an overall better efficacy. Unfortunately, it leads to a higher incidence of severe side effects, namely cardiotoxicity. This work aimed to assess the cytotoxicity of doxorubicin (DOX, also known as...
Main Authors: | Maria Pereira-Oliveira, Ana Reis-Mendes, Félix Carvalho, Fernando Remião, Maria de Lourdes Bastos, Vera Marisa Costa |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-01-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | http://www.mdpi.com/2218-273X/9/1/21 |
Similar Items
-
The Impact of Metformin on the Development of Hypothyroidism and Cardiotoxicity Induced by Cyclophosphamide, Methotrexate, and Fluorouracil in Rats
by: Ahmad H. Alhowail, et al.
Published: (2023-09-01) -
The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells
by: Ana Reis-Mendes, et al.
Published: (2019-03-01) -
Influence of trimetazidine on myocardium energy balance during chemotherapy with doxorubicin and cyclophosphamide
by: A. A. Avagimyan
Published: (2022-06-01) -
Longitudinal melanonychia and distal onycholysis associated with 5-fluorouracil/adriamycin/cyclophosphamide chemotherapy
for breast cancer
by: Marta Żywno, et al.
Published: (2021-12-01) -
Fluorouracil and doxorubicin – cardiotoxic cytostatics in the workplace
by: Małgorzata Kupczewska-Dobecka, et al.
Published: (2020-05-01)